Ultralow prostate-specific antigen nadir after apalutamide: outcomes in synchronous vrsus metachronous metastatic hormone-sensitive prostate cancer
As an ultralow prostate-specific antigen (PSA) nadir (≤0.02 ng/ml) after apalutamide treatment for metastatic hormone-sensitive prostate cancer (mHSPC) was associated with the best oncological outcomes, the question arises as to whether this holds true for both synchronous and metachronous mHSPC. We...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2025
|
| In: |
European urology open science
Year: 2025, Jahrgang: 77, Pages: 19-22 |
| ISSN: | 2666-1683 |
| DOI: | 10.1016/j.euros.2025.05.001 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.euros.2025.05.001 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2666168325001223 
|
| Verfasserangaben: | Mike Wenzel, Thomas Steuber, Carolin Siech, Maximilian Kriegmair, Benedikt Hoeh, Derya Tilki, Axel S. Merseburger, Felix K.H. Chun, Philipp Mandel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1936384469 | ||
| 003 | DE-627 | ||
| 005 | 20250930114510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250922s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euros.2025.05.001 |2 doi | |
| 035 | |a (DE-627)1936384469 | ||
| 035 | |a (DE-599)KXP1936384469 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wenzel, Mike |d 1991- |e VerfasserIn |0 (DE-588)1173350659 |0 (DE-627)1042480494 |0 (DE-576)515171514 |4 aut | |
| 245 | 1 | 0 | |a Ultralow prostate-specific antigen nadir after apalutamide |b outcomes in synchronous vrsus metachronous metastatic hormone-sensitive prostate cancer |c Mike Wenzel, Thomas Steuber, Carolin Siech, Maximilian Kriegmair, Benedikt Hoeh, Derya Tilki, Axel S. Merseburger, Felix K.H. Chun, Philipp Mandel |
| 264 | 1 | |c July 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 3. Juni 2025, Artikelversion: 3. Juni 2025 | ||
| 500 | |a Gesehen am 22.09.2025 | ||
| 520 | |a As an ultralow prostate-specific antigen (PSA) nadir (≤0.02 ng/ml) after apalutamide treatment for metastatic hormone-sensitive prostate cancer (mHSPC) was associated with the best oncological outcomes, the question arises as to whether this holds true for both synchronous and metachronous mHSPC. We addressed this knowledge gap using data from the FRAMCAP (Frankfurt Metastatic Cancer of the Prostate) database. In a cohort of 75 patients with synchronous mHSPC treated with apalutamide, 35% experienced a PSA decline to ≤0.02 ng/ml. Analysis of time to castration-resistant prostate cancer (CRPC) and overall survival (OS) revealed significant differences by PSA nadir category (p < 0.01). In a cohort of 33 patients with metachronous mHSPC treated with apalutamide, 52% experienced a PSA decline to ≤0.02 ng/ml. Analysis of CRPC revealed significant differences by PSA nadir category (p = 0.02). Although there were no significant differences in OS among the PSA nadir categories (p = 0.3), the best numerical OS outcome was observed for PSA ≤0.02 ng/ml. For the overall group of patients achieving PSA ≤0.02 ng/ml, there were no significant difference in time to CRPC and OS between synchronous and metachronous mHSPC. - Patient summary - Apalutamide is a drug for treatment of metastatic prostate cancer that is sensitive to hormone treatment. We found that a decrease in PSA (prostate-specific antigen) to a very low level of ≤0.02 ng/ml after apalutamide treatment can predict good cancer control. This applies to patients with metastasis when they are first diagnosed and to patients who develop metastasis after their diagnosis of prostate cancer. This level of ≤0.02 ng/ml can be used in discussing prognosis and treatment options with these patients. | ||
| 650 | 4 | |a Hormone-sensitive prostate cancer | |
| 650 | 4 | |a Metastatic prostate cancer | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Steuber, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siech, Carolin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kriegmair, Maximilian |d 1987- |e VerfasserIn |0 (DE-588)1049742745 |0 (DE-627)782573347 |0 (DE-576)403726840 |4 aut | |
| 700 | 1 | |a Hoeh, Benedikt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tilki, Derya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Merseburger, Axel S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chun, Felix K. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mandel, Philipp |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology open science |d [Amsterdam] : Elsevier ScienceDirect, 2020 |g 77(2025) vom: Juli, Seite 19-22 |h Online-Ressource |w (DE-627)1734491795 |w (DE-600)3040546-4 |x 2666-1683 |7 nnas |a Ultralow prostate-specific antigen nadir after apalutamide outcomes in synchronous vrsus metachronous metastatic hormone-sensitive prostate cancer |
| 773 | 1 | 8 | |g volume:77 |g year:2025 |g month:07 |g pages:19-22 |g extent:4 |a Ultralow prostate-specific antigen nadir after apalutamide outcomes in synchronous vrsus metachronous metastatic hormone-sensitive prostate cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.euros.2025.05.001 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2666168325001223 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250922 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1049742745 |a Kriegmair, Maximilian |m 1049742745:Kriegmair, Maximilian |d 60000 |d 63100 |e 60000PK1049742745 |e 63100PK1049742745 |k 0/60000/ |k 1/60000/63100/ |p 4 | ||
| 999 | |a KXP-PPN1936384469 |e 477480875X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"outcomes in synchronous vrsus metachronous metastatic hormone-sensitive prostate cancer","title":"Ultralow prostate-specific antigen nadir after apalutamide","title_sort":"Ultralow prostate-specific antigen nadir after apalutamide"}],"language":["eng"],"name":{"displayForm":["Mike Wenzel, Thomas Steuber, Carolin Siech, Maximilian Kriegmair, Benedikt Hoeh, Derya Tilki, Axel S. Merseburger, Felix K.H. Chun, Philipp Mandel"]},"person":[{"family":"Wenzel","display":"Wenzel, Mike","given":"Mike","role":"aut"},{"family":"Steuber","role":"aut","given":"Thomas","display":"Steuber, Thomas"},{"family":"Siech","display":"Siech, Carolin","given":"Carolin","role":"aut"},{"display":"Kriegmair, Maximilian","role":"aut","given":"Maximilian","family":"Kriegmair"},{"role":"aut","given":"Benedikt","display":"Hoeh, Benedikt","family":"Hoeh"},{"family":"Tilki","role":"aut","given":"Derya","display":"Tilki, Derya"},{"family":"Merseburger","role":"aut","given":"Axel S.","display":"Merseburger, Axel S."},{"family":"Chun","display":"Chun, Felix K. H.","role":"aut","given":"Felix K. H."},{"family":"Mandel","display":"Mandel, Philipp","role":"aut","given":"Philipp"}],"origin":[{"dateIssuedDisp":"July 2025","dateIssuedKey":"2025"}],"recId":"1936384469","type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"4 S.","noteIll":"Diagramme"}],"id":{"eki":["1936384469"],"doi":["10.1016/j.euros.2025.05.001"]},"note":["Online verfügbar: 3. Juni 2025, Artikelversion: 3. Juni 2025","Gesehen am 22.09.2025"],"relHost":[{"title":[{"title":"European urology open science","title_sort":"European urology open science"}],"language":["eng"],"part":{"extent":"4","pages":"19-22","volume":"77","text":"77(2025) vom: Juli, Seite 19-22","year":"2025"},"pubHistory":["Volume 19, supplement 1 (January 2020)-"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Ultralow prostate-specific antigen nadir after apalutamide outcomes in synchronous vrsus metachronous metastatic hormone-sensitive prostate cancerEuropean urology open science","id":{"zdb":["3040546-4"],"issn":["2666-1683"],"eki":["1734491795"]},"note":["Gesehen am 23. September 2021"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"1734491795","origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"2020-","publisher":"Elsevier ScienceDirect","publisherPlace":"[Amsterdam]"}]}]} | ||
| SRT | |a WENZELMIKEULTRALOWPR2025 | ||